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Background: The recommendations for the treatment of moderate persistent asthma in the Global Initiative for
Asthma (GINA) guidelines for paediatric asthma are mainly based on scientific evidence extrapolated from studies in
adults or on consensus. Furthermore, clinical decision-making would benefit from formal ranking of treatments in
terms of effectiveness.
Our objective is to assess all randomized trial-based evidence specifically pertaining to 5-18 year olds with
moderate persistent asthma. Rank the different drug treatments of GINA guideline steps 3&4 in terms of
effectiveness.
Methods: Systematic review with network meta-analysis. After a comprehensive search in Central, Medline, Embase,
CINAHL and the WHO search portal two reviewers selected RCTs performed in 4,129 children from 5-18 year old,
with moderate persistent asthma comparing any GINA step 3&4 medication options. Further quality was assessed
according the Cochrane Collaboration’s tool and data-extracted included papers and built a network of the trials.
Attempt at ranking treatments with formal statistical methods employing direct and indirect (e.g. through placebo)
connections between all treatments.
Results: 8,175 references were screened; 23 randomized trials (RCT), comparing head-to-head (n=17) or against
placebo (n=10), met the inclusion criteria. Except for theophylline as add-on therapy in step 4, a closed network
allowed all comparisons to be made, either directly or indirectly. Huge variation in, and incomplete reporting of,
outcome measurements across RCTs precluded assessment of relative efficacies.
Conclusion: Evidence-based ranking of effectiveness of drug treatments in GINA steps 3&4 is not possible yet.
Existing initiatives for harmonization of outcome measurements in asthma trials need urgent implementation.
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Clinical guidelines contain systematically developed state-
ments to help practitioners make optimal healthcare deci-
sions [1]. The Global Initiative for Asthma (GINA)
guideline is a major step forward in achieving best possible
asthma control [2]. The GINA guideline uses symptoms,
exacerbations, airflow limitation, and lung function vari-
ability to categorize asthma severity into intermittent, mild
persistent, moderate persistent or severe persistent. GINA
suggests that 5 to 18 year-olds, whose symptoms are in-
sufficiently controlled after three months of treatment at a
particular GINA step, move up a step (see Table 1).
There is level A evidence (see glossary) on the effect-
iveness of short acting ß2-agonists (SABA; step 1) and
adding a low dose inhaled glucocorticosteroid (ICS)
(step 2) in children with mild asthma [2]. However,
although the level of evidence for GINA step 3&4 recom-
mendations for children older than 5 years is deemed A
to B, level A evidence to guide step-up therapy is lacking
for this age group. Scrutiny of the randomized trials
(RCTs) underlying the guideline, reveals that some are
outdated, because children used daily oral prednisone
(see for example [3,4]), or compare step 2 with step 3
(see for example [5]). This leaves only five RCTs compar-
ing treatments of step 3&4 for this age group [6-10].
Network meta-analysis (NMA), also known as indirect
comparisons, exploits the mathematical property that
(A – B) – (A – C) = A – B – A + C = C – B. It enables
one to formally compare drugs B and C although these
were never compared head-to-head [11-13]. NMA has
major advantages over classic meta-analysis; it formally
ranks treatment effects in case more than two treatments
are involved; it circumvents the usual overrepresentation
of drug comparisons to placebo, which may not always
be the most informative for practising physicians [14].
We set out, using NMA methodology, to compare GINA
step 3&4 drug treatment efficacies in 5 to 18 year-old
children/adolescents with moderate persistent asthma.
Methods
Search strategy
A trained clinical librarian performed a comprehensive
literature search for relevant RCTs in the Cochrane
Central Register of Controlled Trials (Central), Medline
(Pubmed), Embase, CINAHL and ongoing trial registersTable 1 GINA recommended treatment steps for 5 to 18 year
Step 1 Step 2 Step 3 (Select
SABA Low dose ICS A. Medium-or h
B. Low dose ICS
C. Low dose ICS
D. Low dose ICS
SABA = rapidly acting ß2-agonists; ICS = Inhaled Corticosteroids; LABA = Long–actinregistered on WHO Search Portal [15], published until
4 February 2010 (For search details, see Additional file 1).
In addition, two reviewers (LvdM, PhEL) scrutinized refer-
ence lists of included articles, the GINA-guideline and
relevant systematic reviews.
Inclusion and exclusion criteria
We included RCTs conducted in participants aged 5 to
18 years with persistent-moderate asthma and compar-
ing any GINA step 3&4 medication options (see
Additional file 2) to each other or against placebo, with
a follow-up duration of at least four weeks after start of
the intervention. There were no language restrictions.
Acceptable outcome measurements were: spirometry
(forced expiratory volume in 1 second (FEV1), forced
vital capacity (FVC), FEV1/FVC ratio, forced expiratory
flow 25%-75% (FEF25-75), peak expiratory flow (PEF)),
methacholine challenge test (PC20-FEV1), fractional
exhaled Nitric Oxide (FeNO), asthma symptom score,
use of ß2-agonists as breakthrough medication, and
quality of life.
If results did not pertain to the 5 to 18 years age cat-
egory, the trial was excluded with one exception: RCTs
including 4-year olds were included if mean or median
age was between 5 to 18 years. Studies were excluded if
they compared add-on medication to a non-standardised
dose of ICS. Cross-over studies not reporting on treat-
ment effects for each separate treatment period were
also excluded since carry-over effects cannot be
excluded and are extremely difficult to handle [16].
Selection
Two reviewers (LvdM, PhEL) independently assessed
titles and abstracts of all identified citations against the
inclusion criteria. Any disagreements were resolved by
consensus; in case of doubt references were included.
LvdM and PhEL evaluated in full text all papers thus
selected against the inclusion criteria.
Data extraction
LvdM and PhEL extracted, not in duplicate, data on au-
thor, source and year of publication, language, study de-
sign, interventions (medication, way of administration,
dose, and frequency), population summary characteristics
(me(di)an age, asthma severity) and study outcomes. Ifolds
one) Step 4 (Add one or more)
igh dose ICS A. Medium-or high dose ICS + LABA
+ LABA B. LTRA
+ LTRA C. Theophylline
+ Theophylline
g β2-adrenoceptor agonists; LTRA = Leukotriene modifier.
Table 2 Risk of bias in included trials
Study ID[ref] 1
[19]
2
[20]
3
[21]
4
[22]
5
[23]
6
[24]
7
[25]
8
[26]
9
[7]
10
[9]
11
[27]
12
[28]
13
[29]
14
[30]
15
[31]
16
[8]
17
[32]
18
[33]
19
[6]
20
[34]
21
[10]
22
[35]
23
[36]
Y N ?
Sequence generation ? ? ? Y ? Y ? ? Y ? ? ? Y Y ? ? Y ? Y ? Y ? Y 9 0 14
Allocation concealment ? ? Y Y ? ? ? ? Y ? ? ? ? ? ? ? Y ? ? ? ? ? Y 5 0 18
Appropriate blinding of participants ? N Y N ? ? ? Y N Y ? ? ? ? ? ? Y ? Y ? ? N Y 6 4 13
Appropriate blinding of outcome assessors ? Y Y N ? ? ? Y ? Y ? ? ? ? ? ? ? ? ? ? ? N Y 5 2 16
Appropriate blinding of physician ? ? Y N ? ? ? Y ? Y ? ? ? ? ? ? ? ? ? ? ? N Y 4 2 17
Registration of loss to follow-up Y Y ? ? Y Y ? ? Y Y Y Y Y Y Y ? ? Y ? Y Y Y Y 16 0 7
Way missing values were dealt with ? ? ? Y ? ? ? ? Y ? ? ? ? ? ? ? Y Y ? ? ? ? ? 4 0 19
Compliance checked Y ? ? Y Y ? ? ? Y ? ? Y Y Y ? Y ? Y ? ? Y ? Y 11 0 12
Selective reporting ? ? ? ? ? N ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 0 1 22
Total times “Yes” 2 2 4 4 2 2 0 3 5 4 1 3 3 3 1 1 4 3 2 1 3 1 7
Overall score Y/N/? 60 9 138
Each trial could score “yes” for a low, “no” for a high and “?” for an uncertain risk of bias, respectively.
The 9 items are based on a combination of the Cochrane approach to assess the risk of bias, combined with the validity checklist of Jadad et al. [17,18].
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endpoint for each trial arm. To facilitate meta-analysis, we
contacted authors and sponsors of included studies for
additional information such as outcomes expressed on
other scales, (mean) patient characteristics such as height,
and statistics such as standard errors if needed. We asked
for separate data (summaries) of participants in the 5 to
18 years range if the trial had combined this group with
younger or older participants.
Quality assessment
Methodological quality of all included trials was assessed
on 9 items [17,18] (see Table 2). The risk of bias scale
was developed using the Cochrane Collaboration’s tool
for assessing risk of bias [17]. All items were scored as
“yes” for low, “no” for high, and “?” for uncertain risk of
bias, respectively.
Statistical analysis
Many network meta-analyses were based on dichotom-
ous outcomes for each trial. In our study, outcomes were
mostly continuous. To take lung function as an example,
meta-analysis had been possible if, for each treatmentFigure 1 Flowchart from database searches to inclusion of the trials.
the inclusion criteria. Main reasons for exclusion were: reference was not a
dosage, not asthma, follow up duration < 4 weeks or cross-over design.arm, every publication had reported change in mean
FEV1%pred and its standard error after a suitable period
of follow-up. Unfortunately, several trials only reported
FEV1(l) therefore we did some efforts to salvage the
problem by converting the FEV1(l)-value in FEV1%pred.
Ideally, we would have had access to individual patient
data (IPD) for each trial in the review. In our case we
simulated IPD using the summary statistics reported.
We simulated 1000 virtual children from a general
population with age, height and sex distribution based
on the available data on mean age, height and sex per
trial arm. Next, we calculated a corresponding FEV1(l)-
value per virtual child, using existing formula’s. In a final
step, for each trial-arm, we tried to calculate a mean
FEV1%pred and a corresponding SD from the simulated
data, to be used for meta-analysis. (For details on the
statistical analysis see Additional file 3) [37-41].
We also considered the use of Z-scores. However, the
SD was frequently missing and not provided after re-
quest. Furthermore, Z-scores can only be compared if
the average of both outcomes (FEV1(l) and FEV1%pred)
differ by a multiplicative factor, equal to the quotient of
the standard errors. Since there were no studies that7,152 of the 8,175 references were excluded because they did not fulfil
trial, wrong age group or no separate data for < 18 year olds, wrong
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ive standard errors, we could not check whether this
property was approximately correct in our data and
refrained from using this method.
Results
Studies and patients
The comprehensive literature search yielded 8,175 refer-
ences (see Figure 1). We retrieved 200 as full text arti-
cles, representing 160 unique studies. Reference tracking
of the GINA guideline, systematic reviews and included
references did not yield additional references. Twenty-
three trials, conducted between 1984 and 2010, met the
inclusion criteria and were included [6-10,19-36].
Additional file 4 shows the study characteristics of the
23 trials with 4,129 patients ranging in age from 4 to 18
years; we included 6 trials with a lower age range of 4
years, but with a mean or median between 5 and 18
years [6,9,29,31,32,36]. Figure 2 shows the network of
direct and indirect comparisons. There are 28 theoretic-
ally possible pair-wise comparisons: all 7 GINA options
versus placebo and 21 head-to-head comparisons, 3A
versus 3B, . . ., 3A versus 4C, and, taking the otherFigure 2 The network of included trials in GINA step 3&4. ICS = Inhale
Sustained release. The arrows represent the direct comparisons found in th
participants. Except for SR theophylline as add-on to step 3, all treatments
indirect comparison replacing a non-existent comparison is step 3A to 4A,options as a starting point, all the way to 4B versus 4C.
The arrows represent the ten actually published direct
comparisons. The white boxes show the number of
RCTs and total number of participants for each com-
parison. In total, we found seven different head-to-head
comparisons (with between 1 and 7 studies per compari-
son) and 3 different comparisons with placebo (with be-
tween 1 and 8 studies). All indirect comparisons were
possible, except for comparisons with GINA 4c (medium
dose ICS+theophylline as add-on to step 3), which is not
connected to the network. An example of a possible in-
direct comparison replacing a non-existent direct com-
parison is step 3A versus 4A via 3B. A more complicated
example is 3D versus 4A via 4B and 3B. An example
where both direct and indirect comparisons exist would
be 3B vs 3C, namely, direct via a N=63 trial, and indirect
via N=955(899(3B vs Placebo)+56(Placebo vs 3C)) parti-
cipants. The latter example illustrates how NMA may
add strength to scarcely investigated direct comparisons.
Figure 2 shows that 3A versus 3B (N=776), 3B versus
placebo (N=899) and 3B versus 4A (N=1977) are rela-
tively well researched, while most other comparisons de-
pend on weak statistical evidence. However, there ared Corticosteroids; LABA = Long–acting β2-adrenoceptor agonists; SR=
e included RCTs, including the number of RCTs and total number of
are directly or indirectly connected to each other. An example of an
through 3A to 3B, and 3B to 4A.
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3B versus placebo connection, for example, 3A versus
3B, and 3B versus 3C.
The high number of question marks (138/207, or 67%)
in Table 2 indicates that incomplete, unclear or non-
reporting hampered thorough quality assessment. Eleven
out of 23 trials reported on compliance, while only 4
reported on blinding of the physician or how missing
values were dealt with.
Outcome measurements
We found enormous variation in choice of outcome
measures and how they were reported. Twenty-one
studies reported FEV1, but variation in methods of
reporting was quite extreme (Table 3). None of the stud-
ies reported IPD. One study reported the method of
converting “liters” to “percentage of predicted” (e.g.
Quanjer, Zapletal, Polgar or Hankinson) [32]. Thus, al-
though FEV1 is an outcome that 21/23 studies reported
in some form, the results could not be compared
straightforwardly, nor pooled. Pooling outcomes on
asthma symptoms, the second best, was also not possible
(see Additional file 5).
Attempts to salvage the situation
FEV1−values depend on sex, age, and height. FEV1-values
are usually not normally distributed and extreme values
occur, skewing the mean [31]. Besides differences in
reporting of litres and percentages of predicted, the mix of
outcome measures and statistical details was oftenTable 3 Reporting method of FEV1 for all included trials for e
of reporting, at baseline (T0) and endpoint (Te)
Scale of
FEV1
Outcome summary
measure
Referen
reportin
at T0
a
Liter Mean
Mean change
Mean + SE or SD 8, 10, 11
Mean change + SE or SD
Mean + range 14, 15, 1
P-value versus another arm
Difference between arms + 95%CI
% of predicted Mean
Mean change
Mean + SE or SD 2, 3, 5, 6
Mean change + SE or SD
Mean + range 12, 13, 1
P-value versus another arm
Difference between arms + 95%CI
aT0 = baseline of the trial.
bTe = endpoint of the trial, varying from 4 to 56 weeks.
Reporting method of all included trials for each scale (litre or % of predicted) and sreported unsystematically and awkwardly. Intra-arm dif-
ferences instead of between-arm differences were often
reported, while descriptive statistics (standard deviation,
range) were used where inferential statistics (standard
errors, confidence intervals) were needed. These inconsist-
encies or mistakes thwarted our attempts at pooling of
results and made a sensible summary difficult altogether.
We contacted authors or sponsors for more details (e.g.
summaries of patient characteristics for height, IPD, alter-
native outcome measurements such as the mean differ-
ence between the groups with corresponding standard
errors, different time point of follow-up) to allow expres-
sing the results on identical scales. Unfortunately, only in
four instances we received additional information through
these personal communications [7,8,22,34].
We used those trials that reported both FEV1(l) and
FEV1%pred to directly compare our simulation results
with those empirically measured in these trials, and
found that, regrettably, they were very different. In
particular, the ranges of the results were much nar-
rower than the empirically measured percentages of
predicted. In some cases, results from our conversion
method were opposite to the true results (simulated
result of FEV1>100% of predicted versus an observed
result of FEV1<100% of predicted) [6,30,31]. Because
of these considerable and irresolvable discrepancies,
we decided that formal meta-analysis seemed irrespon-
sible. This decision was made easier by the deficient
reporting and potentially low methodological quality
of many trials.ach scale (liter or % of predicted) and statistical method
ce number of study
g summary measure
Reference number of study
reporting summary measure
at Te
b
13, 15, 19
10, 14, 18
, 16, 18, 22, 23 8, 16
23
6, 19 16
10, 14, 15, 18, 19, 23
13, 23
13
11, 12, 18
, 7, 9, 10, 11, 16, 17, 18, 20, 21, 22 2, 3, 6, 7, 9, 16, 17, 20
4, 15, 16, 17, 19 16
11, 12, 18
13, 17
tatistical method of reporting, at baseline (T0) and endpoint (Te).
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Since we are not able to pool the data and establish an
evidence based ranking of effectiveness of drug treat-
ments in GINA steps 3 and 4, we describe the main
findings from the trials of the most frequently compared
interventions (>2 trials/comparison), including over 100
patients per intervention group and having a follow up
of at least 8 weeks. Many different outcomes are
reported. However, in the trial descriptions below we re-
strict our focus to the following clinically most relevant
ones: number of exacerbations, level of control, reliever
medication use, symptom score, frequency of night-time
awakening, quality of life, FEV1, hyperresponsiveness
(PC20-FEV1) and PEF. The only interventions compared
more than two times were steps 3A versus 3B, that is,
adding a LABA to a low dose of ICS or increasing the
dose of ICS, and 3B versus 4A, that is, adding a LABA
to medium or high dose ICS.
Step 3A versus 3B
Three trials [6,32,36] published between 2006 and 2009
compared a medium or high dose ICS to low dose ICS
plus LABA: Gappa et al. (age 4-16 years; n=138 and 145;
QA-score=4/9), Bisgaard et al. (age 4-11 years; N=117,
118 and 106; QA-score=2/9) and De Blic et al. (age 4-11Table 4 Reported significant differences between interventio
Study 3A-3B
Outcome Gappa [32]
Differences
between
groups (95%CI)
Bisgaard [6]
Differences
between
groups (p)
De Blic [36]
Differences
between
groups (95%
Number of
exacerbations
n.a. n.d. n.d.
Level of control p=0.02a 9.8(0.047)b n.d.
Reliever medication
use/reliever
free daysc
8.7(1.2-16.3) n.d. 1.4(0.0-3.4; 0.0
Symptom score
(day&night)
n.d. 0.27(0.024) n.a.
nighttime
awakening
n.a. n.d. n.d.
Quality of life n.a. n.a. n.a.
Lung function
(FEV1)
n.d. n.d. n.d.
Hyperresponsiveness
(PC20-FEV1)
n.a. n.a. n.a.
morning PEF 6.1(1.8-10.4)d n.d. 7.6(1.7-13.5)e
a nr of weeks with successful asthma control.
b asthma-control days (%).
c Percentage of days without rescue medication.
d % of predicted.
e liter.
f For some studies 2 results are presented because three groups were compared in
n.a. = not available.
n.d. = no statistically significant differences.years; N=150 and 153; QA-score=7/9). Bisgaard et al. in a
3-armed trial, compared a fixed low dose of ICS plus
LABA, a non-fixed low dose (‘SMART’) of ICS plus a
LABA and a medium dose of ICS. The authors claim sig-
nificant effects from the SMART ‘regimen compared to
medium ICS or fixed dose. But according to the GINA
classification the two ICS plus LABA regimens are ‘GINA
3A’ and for the purpose of this review we see no additional
value of comparing between these two GINA 3A arms.
We excluded the results of the non-fixed-dose group from
this discussion. Because participants in the non-fixed dose
group were allowed to take additional study medication
(ICS+LABA), only a mean number as-needed-use inhala-
tions (daytime: 0.49 & nighttime: 0.09) in this group is
reported. Regrettably, no range or standard deviation is
mentioned. Therefore it is possible that some participants
were in fact treated according to GINA 4A.
As presented in Table 4, Gappa et al. as well as
Bisgaard et al. found that adding LABA (3A) improved
the level of control statistically significantly more than
doubling the dose of ICS (3B). However, the trial by De
Blic et al. was unable to confirm this. Gappa et al. and
De Blic et al. found a statistically significantly lower use
of rescue medication in the LABA group after 12 weeks
compared to the ICS group, but Bisgaard et al. found non groups per trial
3B-4A
CI; p)
Tal [29]
Differences
between
groups (95%CI)
Morice [30]
Differences
between
groups (95%CI; p)
Pohunek [31]
Differences
between
groups (p)
n.a. n.a. n.a.
n.d. n.d. n.d.
25) n.d. n.d. n.d.
n.d. n.d. n.d.
n.d. n.d. n.d.
n.a. n.d. n.d.
3.75(1.1-6.4)d n.a. 0.08(<0.01)e &
0.06(<0.001)e
n.a. n.a. n.a.
3.77(1.84-5.7)d 9.5(4.2-14.9; <0.001)e
& 10.3(5.0-15.6; <0.001)e,f
15(<0.001)e &
6(<0.001)e,f
the trial.
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ter improvement of the symptom score in the LABA
group compared to the ICS group.
Overall, these larger trials seem to support the view that
there is a larger benefit from adding LABA to a low dose
of ICS than from doubling the dose of ICS (See Table 4).
Step 3b versus 4A
Seven trials [8,10,21,29-31,35] published between 1995
and 2007 compared a medium or high dose of ICS to a
medium or high dose of ICS plus LABA. Three trials
[29-31] contained more than 100 patients per group and
had a follow up of more than 8 weeks: Tal et al. (age 4-
17 years; N=138 and 148; QA-score=3/9), Pohunek et al.
(age 4-11 years; N=213, 201 and 216; QA-score=1/9)
and Morice et al. (age 6-11 years; N=212, 203 and 207;
QA-score=3/9). None of the trials found statistically sig-
nificant differences between the groups on number of
exacerbations, level of control, use of rescue medication,
symptoms scores, nighttime awakenings or quality of
life. As presented in Table 4, Tal et al. and Pohunek
et al. both found a statistically significantly larger benefit
on FEV1 in the LABA group after 12 weeks compared to
the ICS group. All three trials found statistically signifi-
cant differences in favour of LABA on morning PEF
after 12 weeks.
The three studies described here seem to support the idea
that adding LABA to medium dose ICS is slightly more ef-
fective, although as measured by lung function only.
Discussion
We tried to synthesize the evidence for GINA step 3&4
recommendations for 5 to 18 year-olds with moderate
persistent asthma. Our aim was to rank the 21 different
GINA treatment options as to their effectiveness using
standard systematic review methods extended by net-
work meta-analytic techniques.
In principle, the situation looked favourable for network
meta-analysis, with RCTs on six out of seven interventions
either against placebo or head-to-head (Figure 2). Lack of
direct comparisons, for example GINA 3C versus 4A,
could have been compensated by indirect comparisons,
for example through GINA 3B and placebo. Only theo-
phylline was disconnected to the network of trials as we
found no trials in this age group.
Due to extremely different choices trialists made on out-
come reporting methods, we had to abandon attempts at
meta-analysis. Apart from embarking on a set of con-
certed new trials in this area, which may take years to
complete, a potentially quicker way to salvage the situ-
ation with existing data may be joint action among spon-
sors and trialists of existing trials to aggregate their raw
data to inform an IPD meta-analysis [42,43]. The authors
of this review would be more than happy to support suchan endeavour, thereby achieving this review’s original aim.
Such an exercise would depend also on the results of add-
itional trialist-provided information on trial quality, since
pooling of very low quality data is unattractive. This
brings us to the next point. We assessed the risk of bias in
the included trials on a 9-item methodological quality
checklist. We scored “?” if the risk of bias seemed hard to
determine. We scored 138/207 “?”, and this is largely due
to partial, unclear or non-reporting (see Table 2). Adop-
tion and enforcement of the CONSORT statement should
become a priority for trialists and journals alike [44].
After criticizing some of the outcome reporting meth-
ods, let us consider the strengths and limitations of our
own work. We comprehensively searched the literature
and tried to minimize the risk of missing RCTs by track-
ing the references of the GINA-guideline, included RCTs
and relevant systematic reviews [45-47]. However, these
efforts yielded no additional relevant references. We per-
formed all major steps, except the extraction of the
quantitative data in duplicate. Furthermore, our team
had expertise on all aspects of a systematic review: clin-
ical librarian, biostatistician, physician-epidemiologist,
two general practitioners, a trainee general practitioner,
and a paediatric pulmonologist. Nevertheless, our review
is no exception in that it may have been affected by sup-
pression of negative trial results, or publication bias [48].
As far as we are aware, a network meta-analysis on
this subject would have been novel. The majority of the
meta-analyses performed on these treatment options are
combined for paediatric and adult patients. In 2003,
Bisgaard analyzed the effect of long–acting β2-adrenoceptor
agonists (LABA) on the asthma exacerbation rate in
paediatric patients in a review of eight randomized
trials [46]. All trials compared a LABA with a SABA or
placebo in children on inhaled corticosteroids and
reported on exacerbations or asthma-related hospitaliza-
tions in asthmatic children. Bisgaard, while providing the
spectrum of relative risks, refrained from formal meta-
analysis, because of differences in patient populations,
comparators, study design and duration, and definitions of
asthma exacerbation. He concluded that there is no evi-
dence in the existing paediatric literature that LABA pro-
tects against asthma exacerbations, even when used as an
add-on therapy to ICS.
In line with our view that firm evidence to guide step-
up therapy is lacking, Lemanske et al. performed the
BADGER trial, a three-period-cross-over trial in children
eligible for GINA step 3 [49]. The BADGER trial is
clearly relevant to the topic of this review. The study
addresses the research question which of the three medi-
cation options (doubling the dose of the inhaled cortico-
steroid, adding LABA or LTRA) should be the first
choice of treatment in step 3 of the guidelines. Because
of its importance to the research question of this review,
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investigators assigned 182 children, from 6 to 17 years
of age with uncontrolled asthma, despite receiving a low
dose ICS to receive each of three blinded step-up ther-
apies, corresponding with GINA step 3A, 3B and 3C, in
random order for a period of 16 weeks each. Several
clinical and physical aspects were measured, including
the need for oral prednisone, an asthma control test and
FEV1. Main outcome was that overall, LABA as add-on
(GINA 3A) performed better than increasing ICS dose
(GINA 3B) or adding LTRA (GINA 3C). Furthermore,
subgroup analyses were performed to predict the direc-
tion of the patterns of differential response, primary on
baseline values of PC20, Asthma Control Test scores and
genotype, and, post hoc, on demographic and physiological
characteristics. The only significant (p=0.009) predictor was
the baseline Asthma Control Test scores (</≥19) on the
probability of the best response to LABA step-up.
Strengths of the BADGER trial are the topical research
questions and relevant outcomes measures. Further-
more, sensitivity analyses were performed to assess bias,
for example seasonal differences. However, the treatment
period-specific results were not reported separately,
which was the main reason why we could not use the
trial in this review with network meta-analysis. In
addition, the study is hampered by the cross-over design
with possible carry-over effects of ICS treatment. A
wash-out period of four weeks makes using the second
and third treatment periods hazardous due to unquantifi-
able carry-over effects [16]. Carry-over effect of ICS
would have improved the treatment effects of adding
LABA or LTRA. Furthermore, post hoc analysis with rela-
tively small subgroups already raised much discussion
and suggests hypotheses that need more research in stud-
ies with a different design [50-54].
Although GINA provides us with treatment recommen-
dations, steps 3&4 are still not based on sound evidence.
For patients, their parents, and physicians alike, uncertainty
about the best treatment remains. New trials should focus
on add-on therapy to ICS in children. Ongoing and new
RCTs will be part of meta-analysis in a few years. To inter-
pret individual studies, consensus about design and report-
ing of outcome measurements for RCTs would provide a
much better evidence base for the future. In 2009 an official
American Thoracic Society/European Respiratory Society
statement, about standardizing endpoints for clinical
asthma trials and clinical practice was published [55]. A
taskforce formulated recommendations of assessment for
the design, conduct and evaluation of asthma trials for clin-
icians, researchers, and other relevant groups. These
recommendations form an excellent starting point for
harmonization of outcome measures and accompanying in-
ferential statistical measures in RCTs and other compara-
tive effectiveness research. As far back as 1992, Tugwelland Boers introduced a solution for Rheumatoid Arthritis
Clinical Trials, OMERACT (“Outcome Measures in
Rheumatoid Arthritis Clinical Trials”) [56]. OMERACT, an
international informal network, strives to improve outcome
measurement through a data driven, iterative consensus
process involving relevant stakeholder groups. This type of
initiative would be welcome in asthma research too.
Another solution may be prospective meta-analysis
(PMA) [17,42]. PMA meta-analyses RCTs, preferably by
using IPD, that were identified, evaluated and determined
to be eligible for the meta-analysis before the results of
any of those studies become known. PMA was developed
to overcome some of the problems of normal (retrospect-
ive) meta-analyses, mainly to enable hypotheses to be spe-
cified a priori and ignorant of the results of individual
trials. Ideally, PMA provides standardization of clinical
trial procedures, such as study design and data collection
methods, by using, for example, the same instruments and
the same time points for measuring outcomes.Conclusion
Due to extreme variation in choice of outcome measures
and their reporting, firm evidence-based ranking of ef-
fectiveness of the treatment options in GINA 3&4 for 5
to 18 year-olds based on evidence from randomized
trials is currently impossible. Implementation of the
recommendations issued by the recent ATS/ERS task-
force on measures of asthma control in RCTs is urgent.Additional files
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http://www.biomedcentral.com/1471-2466/12/63Glossary of some terms
Level A evidence: a substantial number of well designed RCTs exist, with
substantial numbers of participants, in the recommended population, with
consistent patterns of findings (1).
Level B evidence: few RCTs exist; they are small in size, undertaken in a
different population or results are not consistent (1).
Carry-over effect: the persistence of a treatment applied in one period in a
subsequent period of treatment (2).
Acknowledgements
We would like to thank Ms. F.S. van Etten - Jamaludin, clinical librarian at
Academic Medical Center in Amsterdam, for designing and conducting the
electronic literature searches.
Funding
This study was financially supported by the Netherlands Asthma Foundation
(3.4.06.078) and Stichting Astma Bestrijding (2008/027).
Author details
1Division of Clinical Methods & Public Health, Department of General
Practice, Academic Medical Center-University of Amsterdam, P.O. Box 22700,
Amsterdam 1100 DD, The Netherlands. 2Department of Clinical
Epidemiology, Biostatistics, and Bioinformatics, Academic Medical Center,
Amsterdam, The Netherlands. 3Department of General Practice, Erasmus
Medical Center, Rotterdam, The Netherlands. 4Department of Paediatric
Respiratory Medicine and Allergy, Emma Children’s Hospital – Academic
Medical Center, Amsterdam, The Netherlands.
Received: 28 November 2011 Accepted: 20 September 2012
Published: 15 October 2012
References
1. Jackson R, Feder G: Guidelines for clinical guidelines. BMJ 1998,
317:427–428.
2. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M,
Gibson P, Ohta K, O'Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel
SE, Zar HJ: Global strategy for asthma management and prevention:
GINA executive summary. Eur Respir J 2008, 31(1):143–178.
3. Nassif EG, Weinberger M, Thompson R, Huntley W: The value of
maintenance theophylline in steroid-dependent asthma. N Engl J Med
1981, 304(2):71–75.
4. Brenner M, Berkowitz R, Marshall N, Strunk RC: Need for theophylline in
severe steroid-requiring asthmatics. Clin.Allergy 1988, 18(2):143–150.
5. Malone R, LaForce C, Nimmagadda S, Schoaf L, House K, Ellsworth A,
Dorinsky P: The safety of twice-daily treatment with fluticasone
propionate and salmeterol in pediatric patients with persistent asthma.
Ann Allergy Asthma Immunol 2005, 95(1):66–71.
6. Bisgaard H, Le RP, Bjamer D, Dymek A, Vermeulen JH, Hultquist C:
Budesonide/formoterol maintenance plus reliever therapy: a new
strategy in pediatric asthma. Chest 2006, 130(6):1733–1743.
7. Jat GC, Mathew JL, Singh M: Treatment with 400 mug of inhaled
budesonide vs 200 mug of inhaled budesonide and oral montelukast in
children with moderate persistent asthma: Randomized controlled trial.
Annals of Allergy, Asthma and Immunology 2006, 97:397–401.
8. Meijer GG, Postma DS, Mulder PG, Van Aalderen WM: Long-term circadian
effects of salmeterol in asthmatic children treated with inhaled
corticosteroids. Am J Respir Crit Care Med 1995, 152:1887–1892.
9. Shapiro GG, Mendelson L, Kraemer MJ, Cruz-Rivera M, Walton-Bowen K,
Smith JA: Efficacy and safety of budesonide inhalation suspension
(Pulmicort Respules) in young children with inhaled steroid-dependent,
persistent asthma. J Allergy Clin Immunol 1998, 102(5):789–796.
10. Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF: Addition of
salmeterol versus doubling the dose of beclomethasone in children with
asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Med 1998,
158(1):213–219.
11. Lumley T: Network meta-analysis for indirect treatment comparisons. Stat
Med 2002, 21(16):2313–2324.
12. Lu G, Ades AE, Sutton AJ, Cooper NJ, Briggs AH, Caldwell DM: Meta-
analysis of mixed treatment comparisons at multiple follow-up times.
Stat Med 2007, 26(20):3681–3699.13. Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG:
Methodological problems in the use of indirect comparisons for
evaluating healthcare interventions: survey of published systematic
reviews. BMJ 2009, 338:b1147.
14. Caldwell DM, Ades AE, Higgins JP: Simultaneous comparison of multiple
treatments: combining direct and indirect evidence. BMJ 2005,
331(7521):897–900.
15. WHO: World Health Organisation; a search port for trials. 2010. http://apps.
who.int/trialsearch
16. Senn S: Chapter 1. Introduction & Chapter 3. Carry-over or treatment
by period interaction. In Cross-over Trials in Clinical Research. 2nd
edition. Edited by Senn S, Barnett V. Chichester: John Wiley & Sons, ltd;
2002:p 1-16–35-88.
17. Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of
Interventions. The Cochrane Colloboration. London, UK: John Wiley & Sons;
2009.
18. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ,
McQuay HJ: Assessing the quality of reports of randomized clinical trials:
is blinding necessary? Control Clin Trials 1996, 17(1):1–12.
19. Bennati D, Piacentini GL, Peroni DG, Sette L, Testi R, Boner AL: Changes in
bronchial reactivity in asthmatic children after treatment with
beclomethasone alone or in association with salbutamol. J Asthma 1989,
26(6):359–364.
20. Verini M, Peroni D, Piacentini G, Nicodemo A, Rossi N, Bodini A, Chiarelli F,
Boner A: Comparison of add-on therapy to inhaled fluticasone
propionate in children with asthma: residual volume and exhaled nitric
oxide as outcome measures. Allergy and asthma proceedings 2007,
28(6):691–694.
21. Miraglia Del Giudice M, Piacentini GL, Capasso M, Capristo C, Maiello N,
Boner AL, Capristo AF: Formoterol, montelukast, and budesonide in
asthmatic children: effect on lung function and exhaled nitric oxide.
Respir Med 2007, 101(8):1809–1813.
22. Kondo N, Katsunuma T, Odajima Y, Morikawa A: A randomized open-
label comparative study of montelukast versus theophylline added
to inhaled corticosteroid in asthmatic children. Allergol Int 2006,
55(3):287–293.
23. Boner AL, Piacentini GL, Bonizzato C, Dattoli V, Sette L: Effect of inhaled
beclomethasone dipropionate on bronchial hyperreactivity in asthmatic
children during maximal allergen exposure. Pediatr Pulmonol 1991, 10(1):2–5.
24. Stelmach I, Grzelewski T, Bobrowska-Korzeniowska M, Stelmach P, Kuna P: A
randomized, double-blind trial of the effect of anti-asthma treatment on
lung function in children with asthma. Pulm Pharmacol Ther 2007,
20(6):691–700.
25. Meltzer EO, Kemp JP, Welch MJ, Orgel HA: Effect of dosing schedule on
efficacy of beclomethasone dipropionate aerosol in chronic asthma. Am
Rev Respir Dis 1985, 131(5):732–736.
26. Piacentini G, Sette L, Peroni D, Bonizzato C, Bonetti S, Boner A:
Double-blind evaluation of effectiveness and safety of flunisolide aerosol
for treatment of bronchial asthma in children. Allergy 1990, 45(8):612–616.
27. Shapiro GG, Mendelson LM, Pearlman DS: Once-daily budesonide
inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function
and symptoms of asthmatic children previously receiving inhaled
corticosteroids. Ann Allergy Asthma Immunol 2001, 86(6):633–640.
28. Shapiro GG, Bronsky EA, LaForce CF, Mendelson L, Pearlman D, Schwartz RH,
Szefler SJ: Dose-related efficacy of budesonide administered via a dry
powder inhaler in the treatment of children with moderate to severe
persistent asthma. J Pediatr 1998, 132(6):976–982.
29. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, De Boeck K:
Budesonide/formoterol in a single inhaler versus inhaled corticosteroids
alone in the treatment of asthma. Pediatr Pulmonol 2002, 34(5):342–350.
30. Morice AH, Peterson S, Beckman O, Kukova Z: Efficacy and safety of a new
pressurised metered-dose inhaler formulation of budesonide/formoterol
in children with asthma: a superiority and therapeutic equivalence
study. Pulm Pharmacol Ther 2008, 21(1):152–159.
31. Pohunek P, Kuna P, Jorup C, De Boeck K: Budesonide/formoterol improves
lung function compared with budesonide alone in children with asthma.
Pediatr Allergy Immunol 2006, 17(6):458–465.
32. Gappa M, Zachgo W, Von BA, Kamin W, Stern-Strater C, Steinkamp G: Add-
on salmeterol compared to double dose fluticasone in pediatric asthma:
A double-blind, randomized trial (VIAPAED). Pediatr Pulmonol 2009,
44(11):1132–1142.
van der Mark et al. BMC Pulmonary Medicine 2012, 12:63 Page 11 of 11
http://www.biomedcentral.com/1471-2466/12/6333. Estelle FS: A comparison of beclomethasone, salmeterol, and placebo in
children with asthma. N Engl J Med 1997, 337(23):1659–1665.
34. Ilowite J, Webb R, Friedman B, Kerwin E, Bird SR, Hustad CM, Edelman JM:
Addition of montelukast or salmeterol to fluticasone for protection
against asthma attacks: a randomized, double-blind, multicenter study.
Ann Allergy Asthma Immunol 2004, 92(6):641–648.
35. AstraZeneca Trial: A Six-Month, Randomized, Open-Label Safety Study of
Symbicort (160/4,5microgr) Compared te Pulmicort Turbuhaler in Asthmatic
Children Aged 6 to 11 Years. 2005. http://www.astrazenecaclinicaltrials.com.
Study code: SD-039-0719.
36. De Blic J, Ogorodova L, Klink R, Sidorenko I, Valiulis A, Hofman J,
Bennedbaek O, Anderton S, Attali V, Desfougeres JL, Poterre M: Salmeterol/
fluticasone propionate vs. double dose fluticasone propionate on lung
function and asthma control in children. Pediatr Allergy Immunol 2009,
20(8):763–771.
37. Hankinson JL, Odencrantz JR, Fedan KB: Spirometric reference values from
a sample of the general U.S. population. Am. J. Respir. Crit Care Med
1999, 159(1):179–187.
38. Polgar G: Pulmonary function tests in children. J Pediatr 1979, 95(1):168–170.
39. Quanjer PH, Borsboom GJ, Brunekreef B, Zach M, Forche G, Cotes JE,
Sanchis J, Paoletti P: Spirometric reference values for white European
children and adolescents: Polgar revisited. Pediatr Pulmonol 1995,
19(2):135–142.
40. Zapletal A, Paul T, Samanek M: Die Bedeutung heutiger Methoden der
Lungenfunktionsdiagnostik zur Feststellung einer Obstruktion det
Atemwege bei Kindern und Jugendlichen. Z Erkr Atmungsorgane 1977,
149(3):343–371.
41. WHO: World Health Organisation. 2012. http://www.who.int/en
42. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C:
Traditional reviews, meta-analyses and pooled analyses in epidemiology.
Int J Epidemiol 1999, 28(1):1–9.
43. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG:
Meta-analysis of individual patient data from randomized trials: a review
of methods used in practice. Clin Trials 2005, 2(3):209–217.
44. Schulz KF, Altman DG, Moher D: CONSORT 2010 statement: updated
guidelines for reporting parallel group randomised trials. BMJ 2010,
340:c332.
45. Ni Chroinin M, Lasserson TJ, Greenstone I, Ducharme FM: Addition of long-
acting beta-agonists to inhaled corticosteroids for chronic asthma in
children. Cochrane Database Syst Rev 2009 2009, 8(3):CD007949.
46. Bisgaard H: Effect of long-acting beta2 agonists on exacerbation rates of
asthma in children. Pediatr Pulmonol 2003, 36(5):391–398.
47. Greenstone I, Ni Chroinin M, Lasserson TJ, Ducharme FM: Combination of
inhaled long-acting beta2-agonists and inhaled steroids versus higher
dose of inhaled steroids in children and adults with persistent asthma.
Cochrane Database Syst Rev 2005, 19(4):CD005533.
48. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, Decullier E,
Easterbrook PJ, Von EE, Gamble C, Ghersi D, Ioannidis JP, Simes J,
Williamson PR: Systematic review of the empirical evidence of study
publication bias and outcome reporting bias. PLoS One 2008, 3(8):e3081.
49. Lemanske RF Jr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez
FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Covar RA, Guilbert TW,
Larsen G, Morgan WJ, Moss MH, Spahn JD, Taussig LM: Step-up therapy for
children with uncontrolled asthma receiving inhaled corticosteroids. N
Engl J Med 2010, 362(11):975–985.
50. Baraldi E, Piacentini G: Step-up therapy for children with uncontrolled
asthma. N Engl J Med 2010, 363(1):90–92.
51. Cabana MD: Long-acting beta--agonists best option for "step-up" therapy
for children with uncontrolled asthma. J Pediatr 2010, 157(3):512–513.
52. Lipworth B, Mukhopadhyay S, Palmer C: Step-up therapy for children with
uncontrolled asthma. N Engl J Med 2010, 363(1):91–92.
53. O'Brien F, Aziz I: Step-up therapy for children with uncontrolled asthma.
N Engl J Med 2010, 363(1):90–91.
54. Von ME, Drazen JM: Choosing asthma step-up care. N Engl J Med 2010,
362(11):1042–1043.
55. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW,
Casale TB, Chanez P, Enright PL, Gibson PG, De Jongste JC, Kerstjens HA,
Lazarus SC, Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, SterkPJ, Stoloff SW, Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE: An official
American Thoracic Society/European Respiratory Society statement:
asthma control and exacerbations: standardizing endpoints for clinical
asthma trials and clinical practice. Am J Respir Crit Care Med 2009,
180(1):59–99.
56. OMERACT. 2012. http://www.omeract.org
doi:10.1186/1471-2466-12-63
Cite this article as: van der Mark et al.: A systematic review with
attempted network meta-analysis of asthma therapy recommended for
five to eighteen year olds in GINA steps three and four. BMC Pulmonary
Medicine 2012 12:63.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
